Therefore, the objective of this study was to identify tumor‐derived exosomal biomarkers which are able to discriminate between EGFR mutation and wild‐type NSCLC patients during the early stages of diagnosis, in order to improve the specificity and sensitivity of NSCLC diagnosis using this non‐invasive method. This evidence concerns the gene EGFR and non-small cell lung carcinoma.